BioNTech SE (BNTX) reports strong revenue growth and pipeline progress, while navigating financial and legal hurdles.

Biontech Se Sponsored Adr ( (BNTX)) has released its Q3 earnings. Here is a breakdown of the information Biontech Se Sponsored Adr presented to its investors. BioNTech SE, a cutting-edge global ...

Jefferies analyst Akash Tewari maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $150.00.

Operator Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz ...

BioNTech (BNTX) said on Monday that it expects full-year revenue at the low end of its guidance due in part to inventory write-downs, even as variant-adapted COVID-19 vaccines helped the German ...

Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...

German biotech BioNTech saw its shares rise more than 3% to $114.98 pre-market today, as it reported financial results for the three months ended September 30, 2024, that beat expectations. Revenues ...

On Monday, BioNTech SE (NASDAQ:BNTX) reported third-quarter revenues of 1.244 billion euros (or $1.36 billion), up from 895.3 ...

BioNTech (NASDAQ:BNTX – Get Free Report) will be announcing its earnings results before the market opens on Monday, November ...

Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...

After Pfizer (PFE) posted a third quarter earnings beat and raised its full-year guidance, CEO Albert Bourla joins Market ...

Pfizer (PFE) stock gained after the company beat estimates with its Q3 2024 financials and raised its full-year guidance ...